Jensen Huang's staff letter and Goldman Sachs dropping Claude Code
First things first
There’s a lot of tech drama in the air, from boardroom scrutiny to companies tightening the leash on AI tools and spending. The vibe is less “AI changes everything” and more “okay, but who’s paying, who’s checking, and what actually works?”
Meanwhile, security gaps and shifting rules are making digital life feel less predictable. Still, people are building scrappy things, and the web keeps proving small teams can make something land.
The top 6
Goldman Sachs Is Pulling Claude Code from Its Bankers and Traders
Ask HN: What are you working on? (November 2026)
I'm Not Convinced the AI Bubble Exists
Nvidia Board of Directors Is Investigating Jensen Huang
Outlook.com Is Quietly Rejecting Email from Domains Without DMARC
Support our sponsor
Your Newsletter Deserves Better Than a Free Plan
Quote of the day
I never think of the future. It comes soon enough.
Albert Einstein
Also big today
KetchUp – Open-source SketchUp alternative built with Rust and WebGPU
Unlocking any car from X brand in most of the world
RIP, Harvest
Tesla Hasn't Had a Successful New Product Launch Since JB Straubel Stepped Down
How I Fight AI Brain Fry
Is Opus 5.5 nerfed? Thinking patterns changed on November 3
Pass it on
Enjoying the digest?
Forward it to someone who'd like it, or send them the link to subscribe.
Share hn.todayOne for the road
What did the fish say after swimming into a cement wall?
Dam.
Worth a look
Dux: Free, open-source Wayland desktop shell with file manager and theming
OpenAI Raises $11B at a $1.25T Valuation
RAM Altman: Linux Script Emails Sam Altman Daily How Much Unused RAM in Your PC
Chimera Vocal Synth
Herb Sutter: When a language's creator and its owners strongly disagree [pdf]
The Web Is More Than Enough, by Paul Ford
Song of the day
Deep cuts
Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren't Buying It
Pharmaceutical leaders say AI can help with tasks like identifying drug targets and patients, but it cannot develop effective medicines on its own because biology is too complex. Vertex tested about 50 AI companies on data covering 10,000 compounds without producing a working drug, despite growing investment in AI drug discovery.